A5081575954- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Eosinophilic Disorders and Syndromes
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
- Protein Degradation and Inhibitors
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Hemoglobinopathies and Related Disorders
- Acute Lymphoblastic Leukemia research
- HER2/EGFR in Cancer Research
- Radiomics and Machine Learning in Medical Imaging
- Cancer Genomics and Diagnostics
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Gastrointestinal Tumor Research and Treatment
- Clinical Laboratory Practices and Quality Control
- PI3K/AKT/mTOR signaling in cancer
- Amyloidosis: Diagnosis, Treatment, Outcomes
Centre Hospitalier de Valence
2020-2021
Université Jean Moulin Lyon III
2012-2013
Multiple myeloma (MM) is characterized by copy number abnormalities (CNAs), some of which influence patient outcomes and are sometimes observed only at relapse(s), suggesting their acquisition during tumor evolution. However, the presence micro-subclones may be missed in bulk analyses. Here, we use single-cell genomics to determine how often these high-risk events diagnosis selected relapse.
Sustained imatinib treatment in chronic myeloid leukemia patients can result complete molecular response allowing discontinuation without relapse. We set out to evaluate the frequency of de novo phase patients, identify base-line and under-treatment predictive factors achieving cytogenetic response, assess if is associated with a better outcome. A random selection on front-line therapy (n=266) were considered for inclusion. Complete was confirmed defined as MR 4.5 undetectable BCR-ABL...
Abstract We conducted an observational study (FIRE) to understand the effectiveness and safety outcomes of ibrutinib in patients with chronic lymphocytic leukemia (CLL) France, after a maximum follow-up five years. Patients were included according French marketing authorization 2016 (i.e. relapsed or refractory CLL previously untreated deletion 17p and/or tumor protein p53 mutations unsuitable for chemoimmunotherapy) could have initiated more than 30 days prior their enrolment retrospective...
Background: Tyrosine Kinase Inhibitors (TKIs) discontinuation in patients who had achieved a deep molecular response (DMR) offer now the opportunity of prolonged treatment-free remission (TFR). Patients and Methods: Aims this study were to evaluate proportion de novo chronic-phase chronic myeloid leukemia (CP-CML) sustained DMR identify predictive factors recurrence-free survival (MRFS) after TKI discontinuation. Results: Over period 10 years, 398 CP-CML treated with first-line TKIs...
Abstract Objectives To assess the reduction of transfusions rate in transfusion‐dependent patients with low‐risk myelodysplastic syndrome ( MDS ) iron overload treated deferasirox. Methods Prospective observational study. Primary endpoint was transfusion requirements RTR at 3 months, (assessed on 8‐week period). Secondary endpoints were hematologic improvement according to International Working Group IWG 2006 criteria 3, 6, and 12 months. Results Fifty‐seven evaluable. After months...
The response definitions proposed by the European Leukemia Net (ELN) have been recently modified. We evaluated new criteria for de novo imatinib (400 mg/d) chronic phase myeloid leukemia (CP-CML) patients. Response status according to 2009 and 2013 were determined in 180 unselected Outcome of subgroups patients then compared. classified as optimal responders (OR2009; n = 113, 62.7%), suboptimal (SOR2009; 47, 26.1%) failures (FAIL2009; 20, 11.1%) ELN (OR2013; 77, 42.7%), warnings (WAR2013;...
Abstract Background Tyrosine kinase inhibitors (TKI) can be safely discontinued in chronic phase myeloid leukemia (CP‐CML) patients who had achieved a sustained deep molecular response. Based on the results of discontinuation trials, recommendations regarding patient selection for treatment‐free remission (TFR) attempt been proposed. The aims this study were to evaluate rate eligible TKI and recurrence‐free survival (MRFS) after stop according recommendations. Methods Over 10‐year period,...